v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
OPERATING ACTIVITIES    
Net loss $ (10,659) $ (7,805)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,048 5,028
Stock-based compensation 3,859 2,799
Accretion of acquisition installment payable 62 281
Deferred income taxes 196 (2,445)
Non-cash other 139 0
Changes in certain operating assets and liabilities:    
Accounts receivable - trade (1,497) 1,155
Inventories (1,906) (6,631)
Prepaid expenses and other current assets (519) (953)
Accounts payable - trade 5,207 6,562
Accrued expenses and other liabilities (2,528) (5,049)
Other (1,558) 368
Net cash used in operating activities (4,156) (6,690)
INVESTING ACTIVITIES    
Acquisition of Boston O&P, net of cash acquired 0 (20,693)
Clinic acquisition, net of cash acquired (220) 0
Sale of short-term marketable securities 0 23,474
Investment in private companies (1,540) 0
Purchases of property and equipment (4,227) (6,460)
Net cash used in investing activities (5,987) (3,679)
FINANCING ACTIVITIES    
Payments on mortgage notes (39) (35)
Payments on clinic acquisition notes (87) (538)
Net cash used in financing activities (126) (573)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (79) 1,479
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (10,348) (9,463)
Cash, cash equivalents and restricted cash, beginning of year 45,777 33,027
Cash, cash equivalents and restricted cash, end of period 35,429 23,564
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 1,269 223
Transfer of instruments between property and equipment and inventory (461) 117
Right-of-use assets obtained in exchange for lease liabilities 1,682 347
Issuance of common shares in connection with Boston O&P acquisition $ 233 $ 0